Alirocumab every 2 or 4 weeks significantly reduced LDL-C in pediatric patients with inadequately controlled heterozygous familial hypercholesterolemia.
A healthy lifestyle was associated with reduced risk for CVD among adults with familial hypercholesterolemia regardless of their familial hypercholesterolemia mutation status, researchers reported.“DNA is not destiny; it is not deterministic for familial hypercholesterolemia (FH),” Hayato Tada, MD, PhD, assistant professor in the department of cardiovascular medicine at Kanazawa